Citizens JMP raised the firm’s price target on Enanta (ENTA) to $23 from $21 and keeps an Outperform rating on the shares. Enanta ended Q2 with cash of $193M and guiding to runway at least into fiscal 2028, and continues to advance its immunology pipeline, with the oral KIT and STAT6 candidates displaying good drug-like properties, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA: